In the Clinical Center of Montenegro (KCCG), a hemoport is now available to oncology patients, it was announced today from that health institution.
The announcement states that at the KCCG Institute of Oncology, the project for the availability of a port a cath (hemoport) of central venous access for oncology patients receiving long-term and continuous chemotherapy protocols has been completed.
"In cooperation with the Health Insurance Fund of Montenegro (FZO), AU 'Montefarm' and the full support of the KCCG management, oncology patients now have access to a hemoport (subcutaneous port), a system that is used as a venous access for the application, above all, of chemotherapy, and it is also possible to draw blood, prescribe antibiotics, blood derivatives and infusions through it," the announcement states.
The KCCG added that the interventions, which went smoothly and without complications, were performed on three oncology patients by the expert team of the KCCG, led by the surgeon of the Center for Vascular Surgery, Dr. Tahir Kalač, the specialist in surgery, Dr. Haris Cetković, and the anesthesiologist, Dr. Olga Davidović Vulić. , on Wednesday, December 11, 2024.
"The introduction of another new procedure in our institution, which represents an immeasurable benefit and comfort to oncology patients, is the result of Dr. Kalac's education in the German city of Gelsenkirchen and the cooperation of the Institute of Oncology, the Surgical Clinic, the Clinic for Anesthesia, Reanimation and Pain Therapy, and the Operating Block, to this vascular approach enables safer and more comfortable application of oncology therapy for our patients, especially in situations where oncological protocols include the continuous 48 or 72-hour application of cytostatics, and the application of polychemotherapy protocols, as well as those protocols that are known to often lead to damage to peripheral veins and the possibility of extravasation of cytostatics and damage to the surrounding soft tissues the results of their treatment," the announcement reads.
KCCG said that this opens up some new possibilities, first of all, the introduction of elastomeric pumps for the continuous application of some cytostatics, which would enable patients to be mobile during the 72-hour therapy, go home, reduce hospital days, improve quality of life, reduce hospital treatment costs and workload of the hospital part.
"We hope that in the coming year we will be able to complete this important project," concludes the KCCG announcement.
Bonus video:
